Search: onr:"swepub:oai:prod.swepub.kib.ki.se:152405946" >
Pathologic Response...
Pathologic Response to Neoadjuvant Sequential Chemoradiation Therapy in Locally Advanced Breast Cancer: Preliminary, Translational Results from the French Neo-APBI-01 Trial
- Article/chapterEnglish2023
Publisher, publication year, extent ...
Numbers
-
LIBRIS-ID:oai:prod.swepub.kib.ki.se:152405946
-
http://kipublications.ki.se/Default.aspx?queryparsed=id:152405946URI
-
https://doi.org/10.3390/cancers15072030DOI
Supplementary language notes
-
Language:English
-
Summary in:English
Part of subdatabase
Classification
-
Subject category:ref swepub-contenttype
-
Subject category:art swepub-publicationtype
Notes
-
Background: Radiation therapy (RT), a novel approach to boost the anticancer immune response, has been progressively evaluated in the neoadjuvant setting in breast cancer (BC). Purpose: We aimed to evaluate immunity-related indicators of response to neoadjuvant chemoradiation therapy (NACRT) in BC for better treatment personalization. Patients and Methods: We analyzed data of the first 42 patients included in the randomized phase 2 Neo-APBI-01 trial comparing standard neoadjuvant chemotherapy (NACT) and NACRT regimen in locally advanced triple-negative (TN) and luminal B (LB) subtype BC. Clinicopathological parameters, blood counts and the derived parameters, total tumor-infiltrating lymphocytes (TILs) and their subpopulation, as well as TP53 mutation status, were assessed as predictors of response. Results: Twenty-one patients were equally assigned to each group. The pathologic complete response (pCR) was 33% and 38% in the NACT and NACRT groups, respectively, with a dose-response effect. Only one LB tumor reached pCR after NACRT. Numerous parameters associated with response were identified, which differed according to the assigned treatment. In the NACRT group, baseline hemoglobin of ≥13 g/dL and body mass index of <26 were strongly associated with pCR. Higher baseline neutrophils-to-lymphocytes ratio, total TILs, and T-effector cell counts were favorable for pCR. Conclusion: This preliminary analysis identified LB and low-TIL tumors as poor responders to the NACRT protocol, which delivered RT after several cycles of chemotherapy. These findings will allow for amending the selection of patients for the trial and help better design future trials of NACRT in BC.
Added entries (persons, corporate bodies, meetings, titles ...)
-
Gabelle-Flandin, I
(author)
-
Luong, TMH
(author)
-
Loganadane, G
(author)
-
Ouidir, N
(author)
-
Boukhobza, C
(author)
-
Grellier, N
(author)
-
Verry, C
(author)
-
Thiolat, A
(author)
-
Cohen, JL
(author)
-
Radosevic-Robin, N
(author)
-
Belkacemi, Y
(author)
Related titles
-
In:Cancers: MDPI AG15:72072-6694
Internet link
Find in a library
-
Cancers
(Search for host publication in LIBRIS)
To the university's database
- By the author/editor
-
To, NH
-
Gabelle-Flandin, ...
-
Luong, TMH
-
Loganadane, G
-
Ouidir, N
-
Boukhobza, C
-
show more...
-
Grellier, N
-
Verry, C
-
Thiolat, A
-
Cohen, JL
-
Radosevic-Robin, ...
-
Belkacemi, Y
-
show less...
- Articles in the publication
-
Cancers
- By the university
-
Karolinska Institutet